{'52WeekChange': 0.26862133,
 'SandP52WeekChange': None,
 'address1': '1801 Augustine Cut-Off',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 99.51,
 'askSize': 800,
 'averageDailyVolume10Day': 1313612,
 'averageVolume': 1540185,
 'averageVolume10days': 1313612,
 'beta': 1.036414,
 'beta3Year': None,
 'bid': 99.47,
 'bidSize': 800,
 'bookValue': 8.932,
 'category': None,
 'circulatingSupply': None,
 'city': 'Wilmington',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 101.42,
 'dayLow': 98.29,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -77.622,
 'enterpriseToRevenue': 9.142,
 'enterpriseValue': 20380241920,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 101.75686,
 'fiftyTwoWeekHigh': 110.37,
 'fiftyTwoWeekLow': 62.48,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 183513191,
 'forwardEps': 3.86,
 'forwardPE': 25.756477,
 'fromCurrency': None,
 'fullTimeEmployees': 1456,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00656,
 'heldPercentInstitutions': 0.92403,
 'industry': 'Biotechnology',
 'isEsgPopulated': True,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 967766400,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/incyte.com',
 'longBusinessSummary': 'Incyte Corporation, a biopharmaceutical company, '
                        'focuses on the discovery, development, and '
                        'commercialization of various therapeutics in the '
                        'United States. The company offers JAKAFI, a drug for '
                        'the treatment of myelofibrosis and polycythemia vera '
                        'cancers; and Iclusig, a kinase inhibitor to treat '
                        'chronic myeloid leukemia and philadelphia-chromosome '
                        'positive acute lymphoblastic leukemia. Its clinical '
                        'stage products include ruxolitinib, a drug in Phase '
                        'III clinical trial for steroid-refractory chronic '
                        'graft-versus-host-diseases (GVHD); and Phase II trial '
                        'for the treatment of essential thrombocythemia and '
                        'refractory myelofibrosis. In addition, the company '
                        'engages in the development of itacitinib, which is in '
                        'Phase III clinical trial to treat na√Øve chronic '
                        'GVHD; and pemigatinib that is in Phase II clinical '
                        'trial for treating bladder cancer, '
                        'cholangiocarcinoma, 8p11 myeloproliferative syndrome, '
                        'and Tumor agnostic. Further, it is involved in '
                        'developing Parsaclisib, which is in Phase II clinical '
                        'trial for follicular lymphoma, marginal zone '
                        'lymphoma, and mantel cell lymphoma. Additionally, the '
                        'company develops INCMGA0012 that is in Phase II '
                        'clinical trials for MSI-high endometrial cancer, '
                        'merkel cell carcinoma, and anal cancer, as well as in '
                        'Phase II clinical trials non-small cell lung cancer. '
                        'It has collaboration agreements with Novartis '
                        'International Pharmaceutical Ltd.; Eli Lilly and '
                        'Company; Agenus Inc.; Merus N.V.; Calithera '
                        'Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; '
                        'MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent '
                        'Biologics, Inc.; and Zai Lab Limited. The company was '
                        'founded in 1991 and is headquartered in Wilmington, '
                        'Delaware.',
 'longName': 'Incyte Corporation',
 'market': 'us_market',
 'marketCap': 21611223040,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_332954',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -376048000,
 'nextFiscalYearEnd': 1640908800,
 'open': 100.72,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -11.86,
 'phone': '302 498 6700',
 'previousClose': 101.68,
 'priceHint': 2,
 'priceToBook': 11.130765,
 'priceToSalesTrailing12Months': 9.693701,
 'profitMargins': -0.16868,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 101.42,
 'regularMarketDayLow': 98.29,
 'regularMarketOpen': 100.72,
 'regularMarketPreviousClose': 101.68,
 'regularMarketPrice': 100.72,
 'regularMarketVolume': 800414,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 217372992,
 'sharesPercentSharesOut': 0.032,
 'sharesShort': 6945457,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7017355,
 'shortName': 'Incyte Corporation',
 'shortPercentOfFloat': 0.0378,
 'shortRatio': 4.39,
 'startDate': None,
 'state': 'DE',
 'strikePrice': None,
 'symbol': 'INCY',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.751,
 'twoHundredDayAverage': 88.47734,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '72960770-e83b-3ec3-92c6-dbd8ced339a4',
 'volume': 800414,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.incyte.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19803'}